Table 2 Effects of DGAT1/2 inhibitors on tumor cell growth

Glioblastoma

DGAT1 inhibitor (A-922500)

Suppressed cell proliferation. Induced cell apoptosis and upregulation of CPT1A protein [96, 104, 105]

Inhibition of DGAT1 by shRNA or miRNA-3918

Increased sensitivity of irradiation and prolonged survival of mice [141]

Melanoma

DGAT1 inhibitors (AZD3988, AZD7687, A922500, or T863)

Suppressed cell proliferation and cell cycle progression. Increased the expression of cleaved caspase-3 protein [121]

Gastric cancer

DGAT1 inhibitor (A-922500)

Reduced cell proliferation. Induced apoptosis [147]

Prostate cancer

Inhibition of DGAT1 by siRNA or A-922500

Reduced cell proliferation. Induced of cell cycle G1 arrest and autophagy [122] [116]

Breast cancer

(MCF-7 cells)

DGAT2 inhibitor (PF-06424439)

Inhibited cell proliferation. Induced cell cycle G2/M arrest. Increased sensitivity of radiation. Reduced cell invasive ability. Reduced LD formation [35, 123, 124]

Increased the production of ROS and unrepaired DNA damage of tumor cells after irradiation [123]

Breast cancer

(MDA-231 cells)

DGAT1 inhibitor (A-922500)

Reduced cell proliferation and migratory ability [124]

Ovarian cancer

Knockdown of DGAT1

Inhibited cell proliferation. Reduced cell migration through modulating the EMT process [38]

Gastric cancer

Knockdown of DGAT2

Reduced mesenteric metastatic nodules in the intestinal wall and lung metastasis [39]

Colon cancer

DGAT1 inhibitor (A922500) and DGAT2 inhibitor (PF-06424439)

Inhibition of DGAT1 and DGAT2 decreased tumor growth and reduced the proportion of CD206 + MHCII ^low immunosuppressive myeloid cells in the tumors [150]